Stock ADXN ADDEX THERAPEUTICS LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Addex Therapeutics Ltd Nasdaq

Equities

ADXN

US00654J2069

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-06-27 EDT 		5-day change 1st Jan Change
8.165 USD +2.32% Intraday chart for Addex Therapeutics Ltd -1.51% +34.96%
06-06 Transcript : Addex Therapeutics Ltd, Q1 2024 Earnings Call, Jun 06, 2024
06-06 Addex Therapeutics' Q1 Net Loss Widens; Revenue Down MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Most analysts recommend that the stock should be sold or reduced.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ADDEX THERAPEUTICS LTD Stock Addex Therapeutics Ltd
+34.96% 6.35M -
MODERNA, INC. Stock Moderna, Inc.
+21.85% 46.93B
B-
LONZA GROUP AG Stock Lonza Group AG
+37.63% 39.08B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.05% 38.48B
B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.04% 31.01B
B
CELLTRION, INC. Stock Celltrion, Inc.
-13.75% 26.14B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.65% 25.88B
B-
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+38.43% 12.53B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.92% 11.36B
B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.29% 10.65B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ADXN Stock
  4. ADXN Stock
  5. Ratings Addex Therapeutics Ltd